Protocol Ledger

NCT06931717 · Phase III · RECRUITING

A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior Chemotherapy

Interventional Phase III clinical trial protocol NCT06931717 sponsored by ETOP IBCSG Partners Foundation in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-01-12 Enrollment: 390 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06931717
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)390 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06931717
Protocol FieldVerified Registry Value
NCT IdentifierNCT06931717
Consolidated Lead SponsorETOP IBCSG Partners Foundation
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment390 participants (ESTIMATED)
Registered Start Date2026-01-12
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06931717
Hospital Research SiteLocationSite Profile
CHU d'AngersAngers, FranceOpen Hospital Dossier ->
Fondazione IRCCS Istituto Nazionale dei TumoriMilan, ItalyOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI